Official Title
Assessment of Netosis During COVID-19, Under Treatment With Anakinra, an Interleukin-1 Receptor Antagonist
Brief Summary

During their activation in response to an infectious stimulus or during chronic inflammatory processes, blood and tissue neutrophils modify their functional phenotype and produce numerous toxic mediators. In particular, they rapidly release chromatin filaments covered with numerous granular and cytoplasmic components called "Neutrophil Extracellular Traps" (NETs). This phenomenon, called netosis, has been implicated in many diseases, in particular in viral infections during which this response can be useful for the anti-infectious response at the initial phase, then deleterious when it becomes toxic. for the tissue environment. This has been shown in particular during post-pneumonia acute respiratory distress syndrome. The intensity of netosis is therefore an early factor in activating neutrophils and inflammation. Given the major biological signs of inflammation observed in patients with COVID-19 as soon as they enter the hospital [C-Reactive protein (CRP), Interleukin-6 (IL-6), D-dimers, etc.), it seems particularly interesting to better document this inflammation.

Completed
COVID19
Eligibility Criteria

Inclusion Criteria:

- Patients aged ≥ 18 years

- Patients hospitalized within the Paris Saint-Joseph Hospital Group for whom the
diagnosis of COVID-19 has been established on the basis of a PCR positive for SARS-CoV
19 using a nasal swab and/or a typical chest CT scan

- Patients with a severe or aggravating form of COVID-19, based on an oxygen saturation
≤93% under 6 l/min of nasal oxygen or a saturation ≤93% under 4 l/min oxygen with a
decrease in saturation of at least 3% during the last 24 hours, in ambient air

- Patients treated with Anakinra

- Patients for whom IL-6 assays have been performed

- French speaking patients

Exclusion Criteria:

-

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
France
Locations

Groupe Hospitalier Paris Saint-Joseph
Paris, France

CHU Bichat Claude Bernard
Paris, France

Gilles HAYEM, MD, Principal Investigator
Groupe Hospitalier Paris Saint Joseph

Groupe Hospitalier Paris Saint Joseph
NCT Number
MeSH Terms
COVID-19